← All trials
NCT03731559
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Mar 1, 2019
- Primary completion
- Mar 31, 2021
- Completion date
- Mar 31, 2021
- First posted
- —
- Last posted
- —
- Enrollment
- 200
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- The HIV Netherlands Australia Thailand Research CollaborationLead sponsor
- HIV-NAT Thai Red Cross AIDS Research CenterOverall official - principal investigator
- Klang HospitalCollaborator
- Bhumibol Adulyadej HospitalCollaborator
- Radboud UniversityCollaborator
- Taksin HospitalCollaborator
- Chulalongkorn UniversityCollaborator
- Chonburi Cancer HospitalCollaborator
- Chiangrai Prachanukroh HospitalCollaborator
- Buddhachinaraj HospitalCollaborator
- Government of ThailandCollaborator
- Bamrasnaradura Infectious Diseases InstituteCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.